Constellation Energy Corporation vs 10X Genomics Inc — how do they compare? Constellation Energy Corporation trades at $257.84 (market cap $91.57B), while 10X Genomics Inc trades at $45.9 (market cap $5.81B). The key difference: Constellation Energy Corporation is far larger — about 15.8× 10X Genomics Inc's market cap, and Constellation Energy Corporation pays a 0.67% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| CEG | TXG | |
|---|---|---|
Market Cap | $91.57B | $5.81B |
Sector | Energy | Health |
52-Week High | $403.95 | $45.80 |
52-Week Low | $236.50 | $11.34 |
Enterprise Value | $113.24B | $5.36B |
Dividend Yield | 0.67% | — |
Signals from Pluang's Aura AI — not financial advice
Constellation Energy (CEG) trades at $257.57, up 2.46% today, showing strong momentum despite a bearish technical signal. The stock benefits from robust fundamentals with 2025 revenue of $25.53B and net income of $2.32B, supported by a 70% analyst buy rating and consensus price target of $343.50. Recent news highlights CEG's strategic positioning to capitalize on rising AI-driven electricity demand and nuclear power resurgence.
The outlook remains positive with CEG positioned as a key beneficiary of growing electricity demand from AI and data centers. Investment opportunities include strong earnings growth projections and favorable valuation metrics. Risks include execution challenges in capacity expansion and potential regulatory changes affecting utility operations.
TXG trades at $41.77, down 2.25% today, with a bullish technical setup supported by moving averages. The company shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while recent collaborations with Cleveland Clinic and the Proteintech acquisition expand its diagnostic capabilities. Analyst sentiment is mixed with 45% buy ratings but a consensus price target below current levels.
The outlook suggests cautious optimism as TXG demonstrates operational improvement with positive cash flow generation, though profitability remains elusive. Key risks include execution challenges in new ventures and competitive pressures, while upside potential hinges on continued margin expansion and successful integration of recent acquisitions.
Trailing returns across standard periods
Latest headlines on both assets
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →